
Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome
Keywords: استاندارد مراقبت; AT1R; angiotensin II type-1 receptor; HLA; human leukocyte antigen; AMR; antibody-mediated rejection; CR; cellular rejection; BCR; borderline cellular rejection; AECAs; anti-endothelial cell antibodies; SOC; standard of care; DSA; donor-specific antibody;